

August 7, 2026

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

Ref: Scrip Code: 543322

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: ALIVUS

Dear Sirs,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 – Intimation of Investor/Analyst Meeting

With reference to the captioned subject and pursuant to Regulation 30 and Para A of Part A of Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform the details of Investor/Analyst meet which will be attended by the representatives of the Company:

Date	Name	Mode	Place	Type of Meeting
August 12, 2026	SBI Mutual Fund	In-Person	Mumbai	One on One

The schedule and mode of meeting may undergo a change due to exigencies on part of the Investor/Analyst/Company.

You are requested to kindly take a note of the same.

Thanking You,

Yours Sincerely,

For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

Rudalf Corriea
Company Secretary & Compliance Officer

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)

Corporate Office:

Technopolis Knowledge Park, A wing Office No. 401 to 407,
4th Floor, Mahakali Caves Road, Andheri(E), Mumbai– 400093

Registered Office:

Plot No 170-172, Chandramouli Industrial Estate
Mohol Bazarpeth, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com

